dm+d

Unassigned

New Medicines

IgA nephropathy

Information

New molecular entity
Chinook Therapeutics
Chinook Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Selective inhibitor of the endothelin A receptor
IgAN is characterized by the deposition of IgA-containing immune complexes in glomeruli of the kidney, causin inflammatory response that leads to proteinuria and hematuria. IgAN is the most common primary glomerular disease globally and a leading cause of chronic kidney disease (CKD) [1].
IgA nephropathy
Oral